Press Release

KemPharm Completes its Initial Public Offering

April 28, 2015

Colorado – April 28, 2015 – Cooley advised KemPharm, Inc. on its initial public offering.  KemPharm, based in Coralville, Iowa, is a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs that it believes will be improved versions of widely prescribed, approved drugs. The company trades on The NASDAQ Global Market under the symbol "KMPH."

The Cooley corporate securities team advising KemPharm was comprised of partners Jim Linfield, Brent Siler and Matt Dubofsky and associates Mark Ballantyne, Nathan Jeffries and Bin Wang.

Critical support for the offering was provided by partner Natasha Leskovsek and special counsel Phil Mitchell (health care and life sciences regulatory); partner Thomas Welk (compensation and benefits); and partner Susan Cooper Philpot and senior counsel Bill Morrow (tax).

About Cooley LLP

Cooley's lawyers solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, often where innovation meets the law.

Cooley has 850 lawyers across 12 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.